Press Release: Amber : The Retinal Degeneration Fund announces an investment in Amber Bio
Amber Bio is developing a first-of-its-kind RNA writing platform using multi-kilobase edits to reach previously undruggable patient...
Read full article »
Amber is a California-based biotechnology company that provides gene-editing solutions for physicians to treat genetic disorders.
Read more